About 315 results

ALLMedicine™ Gastrinoma Center

Research & Reviews  102 results

Pancreatic Carcinoid Tumor in a Pediatric Patient.
The American Journal of Case Reports; Musalli DI, Binafif YA et. al.

Apr 9th, 2022 - BACKGROUND Carcinoid tumors are well-differentiated tumors that develop from neuroendocrine cells. They are rare tumors and occur most commonly in the gastrointestinal tract, followed by the pulmonary system. They usually present with abdominal pa...

Development of a quality of life questionnaire for patients with pancreatic neuroendocr...
Journal of Neuroendocrinology; Ramage JK, Friend E et. al.

Feb 15th, 2022 - Pancreatic neuroendocrine tumours (panNET) are heterogeneous neoplasms usually characterised by slow growth and secretion of hormones, which often cause symptoms. The effect of these symptoms on quality of life (QoL) has not previously been examin...

Gastric neuroendocrine neoplasms and precursor lesions: Case reports and literature rev...
Medicine Boeriu A, Dobru D et. al.

Jan 15th, 2022 - Gastric neuroendocrine neoplasms (g-NENs) represent a distinctive group of gastric tumors, stratified into different prognostic categories according to different histological characteristics, put forth in the 2018 World Health Organization classif...

Secretin Stimulation Test and Early Diagnosis of Gastrinoma in MEN1 Syndrome: Survey on...
The Journal of Clinical Endocrinology and Metabolism; Giusti F, Cioppi F et. al.

Dec 19th, 2021 - Multiple endocrine neoplasia type 1 (MEN1) is a rare inherited endocrine cancer syndrome. Multiple gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) affect 30% to 80% of MEN1 patients, with the most common functioning GEP-NET being gastrin...


Dec 3rd, 2021 - Background A gastrinoma is a gastrin-secreting tumor usually found in the pancreas or duodenum. [1, 2] Duodenal wall tumors are frequently small and multiple. Sporadic tumors occurring in the pancreas tend to be solitary and have a greater maligna...

see more →

Drugs  9 results see all →

Clinicaltrials.gov  2 results

Interferon and Octreotide to Treat Zollinger-Ellison Syndrome and Advanced Non-B Islet Cell Cancer

Jul 2nd, 2017 - Heretofore morbidity and mortality in Zollinger-Ellison syndrome were caused by severe ulcer disease. The advent of specific drugs to cure ulcer disease now extends life until metastases from the non-B-islet cell tumor or other events cause death....

Treatment of Zollinger-Ellison Syndrome

Jul 2nd, 2017 - This protocol describes the use of histamine H2-receptor antagonists to control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome. It details which patients will be considered for treatment with these agents, the pretreatment...

see more →

News  11 results

Neuroendocrine Tumors Clinical Practice Guidelines (NCCN, 2021)

Sep 30th, 2021 - Updated clinical guidelines on the diagnosis and management of neuroendocrine and adrenal tumors were released in 2021 by the National Comprehensive Cancer Network (NCCN). The new version of the guidelines, published in the Journal of the National...

Using Somatostatin Analogs in pNETs

Apr 2nd, 2021 - Somatostatin analogs have historically been used for symptom control in patients with pancreatic neuroendocrine tumors (pNETs); however, these agents are now being considered for their antitumor properties. Functional patients with pNETs typically...

Genomic Diversity Clouds Outlook for Neuroendocrine Tumors

Dec 5th, 2020 - Despite a spate of therapeutic advances in recent years, neuroendocrine (NET) tumors remain a poorly investigated collection of cancers whose rarity has limited clinical trial enrollment. Now, genome sequencing studies are providing clues for ther...

Genomic Diversity Clouds Outlook for Neuroendocrine Tumors

Sep 8th, 2016 - Despite a spate of therapeutic advances in recent years, neuroendocrine (NET) tumors remain a poorly investigated collection of cancers whose rarity has limited clinical trial enrollment. Now, genome sequencing studies are providing clues for ther...

March 2015 Quiz 1

Feb 20th, 2015 - ANSWER: D Critique The patient is most likely to have Zollinger-Ellison syndrome (ZES), a condition caused by a gastrinoma. In 25% of cases, ZES is associated with multiple endocrine neoplasia type 1 (MEN-1).

see more →

Patient Education  2 results see all →